COMPARISON OF PATIENT, ONCOLOGIST, AND ONCOLOGY NURSE PREFERENCES FOR ATTRIBUTES OF DRUG THERAPY IN ADVANCED MELANOMA

被引：0
|
作者：
Liu, F. X. [1 ]
Witt, E. A. [2 ]
Ebbinghaus, S. [1 ]
Beyer, DiBonaventura G. [2 ]
Basurto, E. [2 ]
Joseph, R. W. [3 ]
机构：
[1] Merck & Co Inc, N Wales, PA USA
[2] Kantar Hlth, Princeton, NJ USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PP1
引用
收藏
页码：A11 / A11
页数：1
相关论文
共 50 条
  • [31] The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison
    Skedgel, C.
    CURRENT ONCOLOGY, 2016, 23 (05) : 322 - 328
  • [32] Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
    Le, H.
    Coulter, J.
    Cappelleri, J. C.
    Lu, H.
    Quaife, M.
    Meginnis, K.
    Fernandez, G.
    Culver, K.
    Vaghela, S.
    Rifi, N.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S202 - S202
  • [33] Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center
    Stenehjem, David D.
    Au, Trang H.
    Ngorsuraches, Surachat
    Ma, Junjie
    Bauer, Hillevi
    Wanishayakorn, Tanatape
    Nelson, Ryan S.
    Pfeiffer, Constance M.
    Schwartz, Joshua
    Korytowsky, Beata
    Oderda, Gary
    Brixner, Diana, I
    MELANOMA RESEARCH, 2019, 29 (06) : 626 - 634
  • [34] ROLE OF NURSE NAVIGATOR IN IMPLEMENTING INTRALESIONAL DRUG THERAPY FOR NON-RESECTABLE MALIGNANT MELANOMA
    Page, Nancy
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [35] Treatment preferences in advanced pancreatic ductal adenocarcinoma (PDAC) from qualitative patient (PT), caregiver (CG), and oncologist (OC) interviews.
    Lewis, Mark Andrew
    Meginnis, Keila
    Fuldeore, Rupali
    Trapali, Myrto
    Samuelson, Ashley
    Schild, Arianne
    Lamkin, Anica
    deGrazia, Janet
    Harmon, Katrina
    Picozzi, Vincent J.
    Whitty, Jennifer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 712 - 712
  • [36] Comparison of standard gamble utilities and visual analog scale values in an ovarian cancer patient and oncologist study of cancer treatment preferences
    Hess, L. M.
    Skrepnek, G. H.
    Armstrong, E. P.
    Malone, D. C.
    VALUE IN HEALTH, 2008, 11 (03) : A78 - A78
  • [37] Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma
    Matsushita, Shigeto
    Kraehenbuehl, Lukas
    Otsuka, Atsushi
    Mihic-Probst, Daniela
    Cheng, Phil
    Dummer, Reinhard
    Goldinger, Simone M.
    JOURNAL OF DERMATOLOGY, 2015, 42 (09): : 927 - 928
  • [38] Beyond drug therapy: Nonpharmacologic care of the patient with advanced heart failure
    Uretsky, BF
    Pina, I
    Quigg, RJ
    Brill, JV
    MacInerney, EJ
    Mintzer, R
    Armstrong, PW
    AMERICAN HEART JOURNAL, 1998, 135 (06) : S264 - S284
  • [39] Radiation Oncology Providers' Practices and Preferences for Delivering Patient Education on Radiation Therapy: A Mixed Methods Study
    Chen, Jie Jane
    Bredesen, Rheta
    Cooper, S. Lewis
    Du, Kevin
    Garda, Allison E.
    Janchenko, Lauren
    Kim, Ellen
    McAvoy, Sarah A.
    Truong, My-Lien
    Patel, Maitry
    Perni, Subha
    Rooney, Michael K.
    Schone, Sydney
    Shiue, Kevin
    Tonning, Kristi L.
    Warren, Laura E.
    Golden, Daniel W.
    Laucis, Anna M.
    Croke, Jennifer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 116 (03): : E3 - E4
  • [40] UTILITY VALUES ACROSS LINES OF THERAPY IN IMMUNO-ONCOLOGY TREATMENTS: AN EXAMPLE FROM ADVANCED MELANOMA
    Tilden, D.
    Sierakowski, W.
    Cottrell, S.
    Kim, H.
    VALUE IN HEALTH, 2017, 20 (09) : A449 - A449
12345